{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T10:51:50Z","timestamp":1795085510847,"version":"4.10.2"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,10]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Conservative management with progestin is a treatment option for atypical hyperplasia (AH). However, pathologic diagnosis of residual\/recurrent lesions is often problematic because of the profound morphologic changes induced by progestin and the lack of established diagnostic criteria for progestin-treated residual AH.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>We conducted a longitudinal study of 265 endometrial biopsies from 54 patients with a history of AH on progestin therapy. Patient outcomes were divided into 3 categories after morphologic review and immunohistochemical staining with phosphatase and tensin homolog (PTEN) and paired box 2 (PAX2): (1) persistent or residual disease; (2) recurrent disease; (3) complete response. All specimens were classified into 3 categories based on morphology: (1) persistent\/recurrent disease (nonresponse), (2) morphologically uncertain response, (3) optimally treated (complete response). The staining patterns of PTEN\/PAX2 were tracked over time in individual patients and correlated with morphologic findings before and after progestin therapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Our data showed that aberrant expression patterns of PTEN and\/or PAX2 were identified in 48 (88.9%) of the 54 primary biopsies and persisted in persistent\/recurrent AH across serial endometrial biopsies (n=99, <jats:italic toggle=\"yes\">P<\/jats:italic>&lt;0.00001), while normal PTEN and PAX2 expressions were consistently observed in optimally treated cases (n=84, <jats:italic toggle=\"yes\">P<\/jats:italic>&lt;0.00001). More importantly, follow-up biopsies that showed a morphologically uncertain response but a PTEN\/PAX2 expression pattern identical to the initial biopsy were significantly correlated with persistent or recurrent disease (n=18, <jats:italic toggle=\"yes\">P<\/jats:italic>=0.000182), as evidenced by areas with morphologic features diagnostic of AH on subsequent biopsy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Biomarker PTEN\/PAX2 signatures offer a valuable diagnostic aid to identify residual AH in progestin-treated endometrial samples for which the biomarker status from preprogestin treated AH is known. The findings of this study are promising for a possible future change of diagnostic practice.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/pas.0000000000001537","type":"journal-article","created":{"date-parts":[[2020,7,5]],"date-time":"2020-07-05T14:00:58Z","timestamp":1593957658000},"page":"1429-1439","source":"Crossref","is-referenced-by-count":34,"title":["Specific Biomarker Expression Patterns in the Diagnosis of Residual and Recurrent Endometrial Precancers After Progestin Treatment"],"prefix":"10.1097","volume":"44","author":[{"given":"Hao","family":"Chen","sequence":"first","affiliation":[{"name":"Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Lucas","sequence":"additional","affiliation":[{"name":"Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda L.","family":"Strickland","sequence":"additional","affiliation":[{"name":"Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelley","family":"Carrick","sequence":"additional","affiliation":[{"name":"Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Gwin","sequence":"additional","affiliation":[{"name":"Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego H.","family":"Castrillon","sequence":"additional","affiliation":[{"name":"Pathology"},{"name":"Obstetrics and Gynecology"},{"name":"Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glorimar","family":"Rivera-Colon","sequence":"additional","affiliation":[{"name":"Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Niu","sequence":"additional","affiliation":[{"name":"Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle H.","family":"Molberg","sequence":"additional","affiliation":[{"name":"Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxin","family":"Zheng","sequence":"additional","affiliation":[{"name":"Pathology"},{"name":"Obstetrics and Gynecology"},{"name":"Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,7,3]]},"reference":[{"key":"R1-20230922","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/jcp.2004.021071","article-title":"EIN and WHO94","volume":"58","author":"Baak","year":"2005","journal-title":"J Clin Pathol"},{"key":"R2-20230922","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/modpathol.3800328","article-title":"Prediction of endometrial carcinoma by subjective endometrial intraepithelial neoplasia diagnosis","volume":"18","author":"Hecht","year":"2005","journal-title":"Mod Pathol"},{"key":"R3-20230922","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/modpathol.2011.220","article-title":"Reproducibility of endometrial intraepithelial neoplasia diagnosis is good, but influenced by the diagnostic style of pathologists","volume":"25","author":"Usubutun","year":"2012","journal-title":"Mod Pathol"},{"key":"R4-20230922","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1097\/AOG.0b013e3181b190d5","article-title":"Complex atypical endometrial hyperplasia: the risk of unrecognized adenocarcinoma and value of preoperative dilation and curettage","volume":"114","author":"Suh-Burgmann","year":"2009","journal-title":"Obstet Gynecol"},{"key":"R5-20230922","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1097\/00000478-199909000-00014","article-title":"A multicentric European study testing the reproducibility of the WHO classification of endometrial hyperplasia with a proposal of a simplified working classification for biopsy and curettage specimens","volume":"23","author":"Bergeron","year":"1999","journal-title":"Am J Surg Pathol"},{"key":"R6-20230922","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1136\/ijgc-00009577-200403000-00023","article-title":"Risk of progression in complex and atypical endometrial hyperplasia: clinicopathologic analysis in cases with and without progestogen treatment","volume":"14","author":"Horn","year":"2004","journal-title":"Int J Gynecol Cancer"},{"key":"R7-20230922","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ygyno.2004.06.045","article-title":"Hormonal therapy for the management of grade 1 endometrial adenocarcinoma: a literature review","volume":"95","author":"Ramirez","year":"2004","journal-title":"Gynecol Oncol"},{"key":"R8-20230922","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1097\/PAS.0b013e31802d68ce","article-title":"Histologic alterations in endometrial hyperplasia and well-differentiated carcinoma treated with progestins","volume":"31","author":"Wheeler","year":"2007","journal-title":"Am J Surg Pathol"},{"key":"R9-20230922","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ejogrb.2008.02.022","article-title":"The effectiveness of a levonorgestrel-releasing intrauterine system (LNG-IUS) in the treatment of endometrial hyperplasia--a long-term follow-up study","volume":"139","author":"Varma","year":"2008","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"R10-20230922","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.3802\/jgo.2016.27.e8","article-title":"Therapeutic options for management of endometrial hyperplasia","volume":"27","author":"Chandra","year":"2016","journal-title":"J Gynecol Oncol"},{"key":"R11-20230922","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1111\/1471-0528.13763","article-title":"Relapse risk of endometrial hyperplasia after treatment with the levonorgestrel-impregnated intrauterine system or oral progestogens","volume":"123","author":"Orbo","year":"2016","journal-title":"BJOG"},{"key":"R12-20230922","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1053\/j.semdp.2010.09.002","article-title":"Endometrial hyperplasia","volume":"27","author":"Mills","year":"2010","journal-title":"Semin Diagn Pathol"},{"key":"R13-20230922","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1200\/JCO.2009.24.1315","article-title":"Absolute risk of endometrial carcinoma during 20-year follow-up among women with endometrial hyperplasia","volume":"28","author":"Lacey","year":"2010","journal-title":"J Clin Oncol"},{"key":"R14-20230922","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/modpathol.3880050","article-title":"Hormonal pathology of the endometrium","volume":"13","author":"Deligdisch","year":"2000","journal-title":"Mod Pathol"},{"key":"R15-20230922","doi-asserted-by":"crossref","first-page":"4783","DOI":"10.1200\/JCO.2006.06.7173","article-title":"Molecular and pathologic aspects of endometrial carcinogenesis","volume":"24","author":"Hecht","year":"2006","journal-title":"J Clin Oncol"},{"key":"R16-20230922","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/CEJ.0b013e32811080ce","article-title":"From endometrial hyperplasia to endometrial cancer: insight into the biology and possible medical preventive measures","volume":"17","author":"Boruban","year":"2008","journal-title":"Eur J Cancer Prev"},{"key":"R17-20230922","doi-asserted-by":"crossref","first-page":"6225","DOI":"10.1158\/0008-5472.CAN-10-0149","article-title":"Joint loss of PAX2 and PTEN expression in endometrial precancers and cancer","volume":"70","author":"Monte","year":"2010","journal-title":"Cancer Res"},{"key":"R18-20230922","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1309\/AJCP8OMLT7KDWLMF","article-title":"Utility of PAX2 as a marker for diagnosis of endometrial intraepithelial neoplasia","volume":"138","author":"Quick","year":"2012","journal-title":"Am J Clin Pathol"},{"key":"R19-20230922","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/PGP.0000000000000185","article-title":"Pax2 expression in simultaneously diagnosed WHO and EIN classification systems","volume":"34","author":"Joiner","year":"2015","journal-title":"Int J Gynecol Pathol"},{"key":"R20-20230922","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/nrc1778","article-title":"A PANorama of PAX genes in cancer and development","volume":"6","author":"Robson","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"R21-20230922","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/PAS.0b013e3181c89c98","article-title":"PAX2 distinguishes benign mesonephric and mullerian glandular lesions of the cervix from endocervical adenocarcinoma, including minimal deviation adenocarcinoma","volume":"34","author":"Rabban","year":"2010","journal-title":"Am J Surg Pathol"},{"key":"R22-20230922","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Kandoth","year":"2013","journal-title":"Nature"},{"key":"R23-20230922","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1111\/jcmm.12090","article-title":"Deregulation of PAX2 expression in renal cell tumours: mechanisms and potential use in differential diagnosis","volume":"17","author":"Patricio","year":"2013","journal-title":"J Cell Mol Med"},{"key":"R24-20230922","first-page":"3254","article-title":"PTEN mutations and microsatellite instability in complex atypical hyperplasia, a precursor lesion to uterine endometrioid carcinoma","volume":"58","author":"Levine","year":"1998","journal-title":"Cancer Res"},{"key":"R25-20230922","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1158\/2159-8290.CD-11-0039","article-title":"High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability","volume":"1","author":"Cheung","year":"2011","journal-title":"Cancer Discov"},{"key":"R26-20230922","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.humpath.2012.08.005","article-title":"Epidermal growth factor receptor, phosphatidylinositol-3-kinase catalytic subunit\/PTEN, and KRAS\/NRAS\/BRAF in primary resected esophageal adenocarcinomas: loss of PTEN is associated with worse clinical outcome","volume":"44","author":"Bettstetter","year":"2013","journal-title":"Hum Pathol"},{"key":"R27-20230922","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2174\/156800908784293659","article-title":"The PTEN\/PI3K\/AKT signalling pathway in cancer, therapeutic implications","volume":"8","author":"Carnero","year":"2008","journal-title":"Curr Cancer Drug Targets"},{"key":"R28-20230922","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/PGP.0b013e31802e4696","article-title":"Benign endometrial hyperplasia sequence and endometrial intraepithelial neoplasia","volume":"26","author":"Mutter","year":"2007","journal-title":"Int J Gynecol Pathol"},{"key":"R30-20230922","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.ygyno.2003.11.026","article-title":"Involution of PTEN-null endometrial glands with progestin therapy","volume":"92","author":"Zheng","year":"2004","journal-title":"Gynecol Oncol"},{"key":"R31-20230922","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/PGP.0b013e318226b376","article-title":"PAX2 loss by immunohistochemistry occurs early and often in endometrial hyperplasia","volume":"31","author":"Allison","year":"2012","journal-title":"Int J Gynecol Pathol"},{"key":"R32-20230922","first-page":"4311","article-title":"Molecular identification of latent precancers in histologically normal endometrium","volume":"61","author":"Mutter","year":"2001","journal-title":"Cancer Res"},{"key":"R33-20230922","doi-asserted-by":"crossref","first-page":"5613","DOI":"10.1158\/0008-5472.CAN-05-4321","article-title":"Regression of latent endometrial precancers by progestin infiltrated intrauterine device","volume":"66","author":"Orbo","year":"2006","journal-title":"Cancer Res"},{"key":"R34-20230922","first-page":"6401","article-title":"Expression of PAX2 and PTEN correlates to therapy response in endometrial hyperplasia","volume":"35","author":"Orbo","year":"2015","journal-title":"Anticancer Res"}],"container-title":["American Journal of Surgical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000001537","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T22:59:26Z","timestamp":1695423566000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000001537"}},"subtitle":["A Longitudinal Study"],"short-title":[],"issued":{"date-parts":[[2020,7,3]]},"references-count":33,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/pas.0000000000001537","relation":{},"ISSN":["0147-5185"],"issn-type":[{"value":"0147-5185","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7,3]]}}}